Shigeo Koido, Toshifumi Ohkusa, Kazuki Takakura, Keisuke Saito, Zensho Ito, Hiroko Kobayashi, Mikio Kajihara, Kan Uchiyama, Seiji Arihiro, Hisao Tajiri, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Chiba 277-8567, Japan.
World J Gastroenterol. 2013 Dec 14;19(46):8531-42. doi: 10.3748/wjg.v19.i46.8531.
The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation therapy can improve survival rates, it is imperative to integrate alternative strategies such as immunotherapy to improve outcomes for patients with advanced CRC. In this review, we will discuss the effect of immunotherapy for inducing cytotoxic T lymphocytes and the major immunotherapeutic approaches for CRC that are currently in clinical trials, including peptide vaccines, dendritic cell-based cancer vaccines, whole tumor cell vaccines, viral vector-based cancer vaccines, adoptive cell transfer therapy, antibody-based cancer immunotherapy, and cytokine therapy. The possibility of combination therapies will also be discussed along with the challenges presented by tumor escape mechanisms.
结直肠癌(CRC)的发病率呈上升趋势,而复发性或转移性疾病患者的预后极差。虽然化疗和放疗可以提高生存率,但必须整合免疫疗法等替代策略,以改善晚期 CRC 患者的预后。在这篇综述中,我们将讨论免疫疗法诱导细胞毒性 T 淋巴细胞的作用,以及目前正在临床试验中的 CRC 的主要免疫治疗方法,包括肽疫苗、基于树突状细胞的癌症疫苗、全肿瘤细胞疫苗、基于病毒载体的癌症疫苗、过继细胞转移疗法、抗体类癌症免疫疗法和细胞因子疗法。还将讨论联合治疗的可能性,以及肿瘤逃逸机制带来的挑战。